Auricular Vagus Nerve Stimulation Combined with Physical Therapy for Individuals with Parkinson's Disease: A Pilot Randomized Sham-controlled Trial.

Alexandra Evancho, DPT[1*], Jennifer Dawson, DPT[2], Harrison Walker, MD[3], Christopher Ballmann, PhD[4], and William J. Tyler, PhD[5]

[1]Department of Physical Therapy and Center for Engagement in Disability Health and Rehabilitation Sciences, University of Alabama at Birmingham (UAB), School of Health Professions, Birmingham, Alabama 35294 USA [2]Birmingham Veterans Affairs, Birmingham, AL 35294 USA [3]Department of Neurology, UAB Heersink School of Medicine [4]Department of Kinesiology, UAB, School of Education [5]Department of Biomedical Engineering and Center for Neuroengineering and Brain Computer Interfaces, UAB School of Engineering and UAB Heersink School of Medicine

ABSTRACT

Background and Purpose: Both neuromodulation and physical therapy have been shown to mitigate motor and non-motor symptoms of Parkinson's Disease. Few studies have examined the integration of noninvasive neuromodulation with physical therapy approaches for improving Parkinsonian symptoms. The purpose of this study was to investigate the safety, feasibility, and potential synergistic effects of combining transcutaneous auricular vagus nerve stimulation (taVNS) with physical therapy for enhancing the therapeutic benefits of exercise as medicine in a clinical setting.

Methods: This pilot study was designed as a randomized, sham-controlled clinical trial. Participants (N=20) were randomly assigned to receive active or sham-taVNS in combination with physical therapy for 12 visits over 6 weeks. We quantified safety, tolerability, and feasibility outcomes, as well as changes in cardiovascular and motor function over time.

Results: We observed taVNS was well tolerated without reported adverse events. Our observations further revealed taVNS administered prior to physical therapy improves cardiovascular regulation at rest and during exercise. Administering taVNS prior to exercise also led to significant and sustained improvements in motor function and balance over time.

Discussion and Conclusions: Combining taVNS with physical therapy was safe and tolerable. We found taVNS enhances motor improvements from physical therapy, in part, by modulating cardiovascular function during exercise. These observations support larger trials investigating the integration of taVNS into physical therapy interventions for Parkinson's Disease.

Trial Registration: ClinicalTrials.gov NCT05871151.

*Correspondence email: AE amelgin@uab.edu

INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized by both motor and non-motor symptoms[1]. While not curative, exercise is a well-established and effective non-pharmacologic therapy that reduces symptom severity and potentially attenuates disease progression[2,3]. Physical Therapy (PT) is frequently prescribed for individuals with PD and provides a structured, reimbursable setting for safe participation in exercise. However, translating evidence-based exercise protocols into routine PT care is often hindered by practical limitations and disease-specific barriers that are typically not accounted for during clinical trials[4,5]. Neuromodulation is a promising therapeutic approach that is increasingly explored as an add-on to rehabilitation to enhance recovery and restore function for patients with neurological conditions[6]. Despite this promise, neuromodulation has not been systematically tested as a strategy to overcome PD-specific exercise barriers within standard PT practice.

Vagus Nerve Stimulation (VNS) is as neuromodulatory method that may specifically address barriers that limit the impact of exercise for PD in the clinical setting[6]. VNS involves the surgical implantation of a pulse generator that delivers electrical current to the Vagus Nerve (VN) as it courses through the neck. Although the therapeutic effects of VNS are not fully understood, it can modulate cardiovascular (CV) autonomic activity[7] and immune function[8], increase arousal/attention[9], and facilitate learning[10] and memory consolidation[11]. Exercise programs for PD such as LSVT-BIG® and high-intensity aerobic training protocols (e.g., SPARX trials) have been shown to improve both motor and non-motor symptoms[12-16]; however, the prescribed treatment frequency and intensity is often logistically challenging, limiting clinical translation. Combining VNS with an adapted, more flexible exercise protocol could address this barrier by enhancing learning and memory to augment the efficacy and durability of rehabilitation interventions that are more suitable to clinical practice[17,18]. Additionally, because of the VN's innervation of the heart, VNS is increasingly investigated to treat CV dysfunction in a variety of diseases and disorders[7,19]. In PD, autonomic nervous system (ANS) dysfunction (dysautonomia) can blunt the cardiovascular (CV) system's response to exercise[20-23], which may limit the ability to achieve target heart rates during training and reduce the effectiveness of exercise interventions. Therefore, VNS could be used to enhance CV efficiency and improve exercise capacity and tolerance in PD. However, the wide-spread clinical impact of implanted VNS is limited by stimulation-associated adverse events (e.g. paresthesia, headache, bradycardia)[24] associated with this invasive neuromodulation approach, making it less practical and translatable to clinical practice.

Transcutaneous auricular Vagus Nerve Stimulation (taVNS) is a non-invasive alternative to VNS that targets the auricular branch of the Vagus Nerve (ABVN) through the skin of the external ear. Using low-intensity, pulsed electrical currents, taVNS improves the safety and scalability of VNS with similar therapeutic effects[25-27]. Given PTs familiarity with transcutaneous electrical nerve stimulation (TENS), taVNS could be a practical and low-risk adjunct intervention to enhance rehabilitation outcomes. TaVNS has been explored as a potential standalone therapy for PD[28-31], and has been investigated in combination with PT in other patient populations[32-34]. However, taVNS has not been tested alongside PT in individuals with PD. This Phase I study aimed to establish and test a protocol for combining taVNS with PT in individuals with PD, with the primary goal of evaluating safety, tolerability, and feasibility. This work is intended to inform future trials investigating the potential therapeutic benefits of this combined intervention.

METHODS

Trial Design and Regulatory Oversight

This single-blinded, parallel-group, Phase I RCT involved 16 visits: screening, baseline motor assessment, 12 treatment sessions over six weeks, a post-test assessment, and a four-week follow-up visit (**Figure 1**). Cognitive outcomes and quality of life outcomes were collected at each assessment but are beyond the scope of this paper. Participants were randomized at a 1:1 allocation ratio into 1 of 2 groups: (1) active taVNS plus PT or (2) sham taVNS plus PT. All assessment visits were conducted in

the “OFF” medication state (12-hours no medication prior to the visit). Written informed consent was obtained prior to enrollment and study participation. The study protocol was approved by the University of Alabama at Birmingham IRB and registered on ClinicalTrials.gov (NCT05871151).



Figure 1. Overview of Study Design.

Participants

Participants were recruited through UAB’s Movement Disorders Clinic, local support groups, and patient advocacy organizations. Inclusion criteria were (1) idiopathic PD diagnosis, (2) age 35–80, (3) stable medications, (4) no falls in 6 weeks, (5) ability to walk without aids, and (6) neurologist approval to participate. Exclusion criteria were: (1) moderate-severe cognitive impairment (MoCA <20); (2) psychiatric comorbidities; (3) co-morbid CV or neurologic disorders including Bells Palsy; (4) implanted devices; (5) history of seizures and/or vasovagal syncope; and (6) pregnancy. Interested participants first completed a phone eligibility screen. Those eligible were invited for in-person cognitive screening and consent. After eligibility was confirmed and physician approval obtained, participants were consented and enrolled.

Interventions

Participants completed 12 sessions (2–3/week) over six weeks reflecting typical PT care. All treatment visits occurred in the “ON” medication state. Each 60-minute session began with baseline heart rate (HR) and blood pressure (BP), followed by 15 minutes of active or sham taVNS while resting. Study staff remained present and reassessed HR/BP post-stimulation. Participants then completed a 45-minute one-on-one PT session with a PD-trained clinician, followed by post-exercise vitals. The only difference between groups was the electrical current output of the taVNS device.

Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)

Bilateral taVNS was delivered using a small, current-controlled device (vagus.net) connected to conductive, hydrogel earbud electrodes (BRAIN Buds; IST, LLC) inserted into the external acoustic meatus (**Figure 2A**). Skin was inspected before and after each use. Biphasic pulses (250 µsec pulse durations, 50 µsec inter-pulse interval) were delivered at 30 Hz and 1.0 to 4.0 mA, which was adjusted by study staff for comfort as necessary. These settings were chosen based on a combination of findings from both animal studies and clinical trials involving individuals with PD[28,29,31,35,36]. Sham devices mimicked controls but delivered 0 mA current.

PWR! Moves Physical Therapy Treatment

PWR! Moves®, developed by the creator of LSVT BIG®, applies the same principles of LSVT BIG® within a more flexible and adaptable framework that is more suitable to translation into clinical practice[37]. PWR! Moves® is increasingly utilized in the clinic and was therefore selected as the standard PT platform for this study to provide a relevant foundation for testing whether adjunctive taVNS can enhance motor outcomes in the clinic. Participants in both groups completed 45-minute PWR! Moves PT session with a PWR! Moves Certified Clinician. The program includes 4 basic movements labeled PWR! Up, Rock, Twist, and Step, targeting antigravity extension, weight shifting, axial mobility, and transitional movements. Each movement can be performed in standing, sitting, quadruped, prone, or supine positions



Figure 2. A) Hydrogel earbud electrodes were used and inserted into the external acoustic meatus. The participant sat comfortably in a chair for the duration of the taVNS treatment. B) The PWR! Moves exercise protocol includes movements that target antigravity extension, weight shifting, axial mobility, and transitional movements. These movements can be performed in standing, sitting, quadruped, prone, or supine positions.

(**Figure 2B**). Sessions were tailored to each participant's ability level, with emphasis on large amplitude and high effort during sessions. Progression and prescription of all movements were determined by the clinician. Patient specific deficits (whether self-reported or noted during motor function assessments) were considered in treatment sessions.

Outcome Measures

Safety and feasibility metrics[38] included 1) recruitment, enrollment, and attrition rates; 2) adverse events experienced during stimulation or exercise; and 3) tolerability. Changes in the Movement Disorders Society Unified Parkinson's Disease Rating Scale Motor Sub-Scale (MDS-UPDRS Part III) were assessed over three time points to assess trends in treatment response: 1) baseline (assessment 1), 2) immediate post-treatment (assessment 2), and at 4-weeks follow-up (assessment 3). This measure was administered at the start of each visit to minimize fatigue effects. Additional outcome measures included a series of clinical tests commonly used in PT practice, including the Modified Clinical Test of Sensory Interaction and Balance (mCTSIB; measure of static balance), Functional Gait Assessment (FGA; measure of dynamic balance, score out of 30, higher scores indicate better balance), Mini Balance Evaluation Systems Test (mini-BEST; measure of static and dynamic balance, score out of 28, higher scores indicate better balance), Six-Minute Walk Test (6MWT; measure of CV endurance, measures distance walked in 6 minutes in feet), and the 10-meter walk test (10MWT-ss and 10MWT-fs, which measures the time taken to walk 10 meters at self-selected and fastest gait speeds). Additionally, CV response to stimulation and exercise was measured at each treatment visit by assessing changes in HR, systolic blood pressure (SBP), and diastolic blood pressure (DBP) by measuring these variables at three time points: 1) pre-taVNS, 2) immediately post-taVNS, and 3) immediately post-exercise. All data was collected on-site at UAB's Wellness, Health, and Research Facility (WHARF).

Study Participants

We targeted a sample size of 20 (10 per group) based on the projected number of individuals that could be recruited, screened, enrolled, and retained within the study period. The study PI enrolled participants and assigned participants to interventions using RedCap's randomization module. Participants were blinded to treatment groups throughout the duration of the study using a standardized blinding script. Due to the small study team and limited personnel resources, the PI was not blinded to group assignment. All other study staff involved in assessments and intervention delivery remained blinded throughout the study to reduce potential bias.

Statistical Analysis

Feasibility and safety outcomes including recruitment, enrollment, attrition, and adverse events were summarized using frequency counts and percentages. Descriptive statistics were calculated for baseline demographic and clinical variables. Baseline differences and tolerability were compared using independent t-tests and chi-square tests, as appropriate.

Ancillary exploratory within-group analyses of motor outcomes (MDS-UPDRS III, gait, and balance) are reported descriptively and included repeated measures ANOVAs with Bonferroni corrections for multiple comparisons as appropriate. CV responses (HR, SBP, DBP) were analyzed using paired t-tests for pre/post-taVNS and pre-taVNS/post-exercise intervals. Effect sizes were reported using Cohn's d along with 95% confidence intervals. Between-group comparisons of change scores were conducted for outcomes showing within-group significance using two-tailed t-tests. Change scores for motor outcomes were calculated from baseline to post-treatment (immediate effect) and from baseline to follow-up (sustained effect). Change scores for CV outcomes were calculated from pre-taVNS to post-taVNS (to elucidate effect of taVNS alone) and from pre-taVNS to post-exercise (to elucidate effect of taVNS plus PT). These exploratory comparisons are intended to inform effect size estimation and outcome selection for a future definitive trial. Analyses were conducted using JASP (version 0.18.3), with significance set at $p < 0.05$.



Figure 3. Consort Diagram

RESULTS

Feasibility

We screened 44 individuals of which 33 met preliminary criteria and 26 were consented and enrolled between May 2023 and Sept 2024. The study was completed once recruitment goals were met. Three subjects were excluded after in-person screening, yielding a 70% enrollment rate (23/33). One participant was excluded pre-randomization due to hypertension. Twenty-two participants were randomized (11 per group). One sham participant withdrew due to an unrelated illness, and one active participant missed follow-up, resulting in a 91% completion rate and 95% adherence. A total of 20 participants (10 per group) were included in the final analyses. See **Figure 3** for the CONSORT diagram.

Demographics and Clinical Characteristics

Baseline demographic and clinical characteristics are presented in **Table 1**. Participants averaged 67.2 ± 7.1 years of age, with PD duration of 5.0 ± 3.2 years and mild-moderate disease severity (H&Y 1-3). There were no significant between-group differences in age (p=0.143, CI: -1.75, 11.15), years since diagnosis (p=0.813, CI: -3.42, 2.72), H&Y stage (p=0.382, CI: -3.42, 2.72), cognitive function (MoCA OFF: p=0.640, CI: -2.71, 1.71; MoCA ON: p=0.723, CI: -2.74, 1.94), and ethnic composition (p=0.305). Sex and gender distributions were identical across groups. There were no significant differences in MDS-UPDRS Part III scores at baseline in the OFF- (sham: 36.7 ± 8.6, active: 31.0 ± 12.68) and ON-medication (sham: 34.2 ± 14.66, active: 26.3 ± 13.21) states (OFF: p=0.255, CI: -4.48, 15.88; ON: p=0.222, CI: -5.21, 21.01).

Table 1. Baseline Demographic and Clinical Characteristics by Group

Characteristic	Total (N=20)	Sham (n=10)	Active (n=10)	p-value	95% CI
Age, years	67.2 (7.10)	69.5 (6.15)	64.8 (7.51)	0.143	-1.75, 11.15
Years since diagnosis	5.0 (3.18)	4.8 (3.05)	5.2 (3.47)	0.813	-3.42, 2.72
Hoehn & Yahr stage	2.7 (0.75)	2.8 (0.63)	2.5 (0.85)	0.382	-0.40, 1.00
MDS-UPDRS Part III (Off)	33.9 (10.95)	36.7 (8.6)	31.0 (12.68)	0.255	-4.48, 15.88
MDS-UPDRS Part III (On)	30.3 (14.17)	34.2 (14.66)	26.3 (13.21)	0.222	-5.21, 21.01
MoCA (Off)	27.0 (2.31)	26.7 (1.95)	27.2 (2.70)	0.640	-2.71, 1.71
MoCA (On)	26.7 (2.43)	26.5 (2.37)	26.9 (2.60)	0.723	-2.74, 1.94
Sex					
Male	16 (80.0%)	8 (80.0%)	8 (80.0%)	1.000	
Female	4 (20.0%)	2 (20.0%)	2 (20.0%)		
Gender					
Male	16 (80.0%)	8 (80.0%)	8 (80.0%)	1.000	
Female	4 (20.0%)	2 (20.0%)	2 (20.0%)		
Ethnicity					
White/Caucasian	19 (95.0%)	10 (100.0%)	9 (90.0%)	0.305	
Black/African-American	1 (5.0%)	0 (0.0%)	1 (10.0%)		

Note: *Independent samples t-tests were used for continuous variables and chi-square test for categorical variables. *A p-value of 0.05 was considered statistically significant. Confidence intervals are reported for continuous variables.*

Safety and Tolerability of Treatment

There were no adverse events reported throughout the duration of the study that were directly attributable to the study treatment. Tolerability results (**Table 2**) showed participants in the active group were more likely to perceive the stimulation (p=0.021). 33.3% of participants in the active group reported feeling the stimulation every time and 55.6% most of the time, while the sham group reported only occasional (50.0%) or rare (50.0%) perception of stimulation. Perceived stimulation intensity ratings (0–10 scale) were higher in the active group (3.0 ± 1.89) compared to the sham group (0.9 ± 1.29; p=0.009, CI: -3.62, -0.58), however an average rating of 3.0 in the active group indicates that the intensity was

perceived as relatively mild. Tingling was the most frequently reported sensation (70% active vs. 40% sham), followed by a pulsating sensation (30% active, 0% sham). No participants reported pain or discomfort.

Table 2. Tolerability Survey Results by Group

	Sham (n=10)	**Active** (n=10)	**p-value**
Feels Stimulation			**0.021***
Yes	0 (0.0%)	4 (40.0%)	
Sometimes	4 (40.0%)	4 (50.0%)	
No	6 (60.0%)	1 (10.0%)	
If yes/sometimes, frequency felt			**0.020***
Every Time	0 (0.0%)	3 (33.3%)	
Most of the Time	0 (0.0%)	5 (55.6%)	
Occasionally	2 (50.0%)	1 (11.1%)	
Rarely	2 (50.0%)	0 (0.0%)	
Stimulation Intensity (0–10)	0.9 (1.29)	3.0 (1.89)	**0.009*** (CI: -3.672, -0.58)
Tingling Sensation			0.178
Yes	4 (40.0%)	7 (70.0%)	
No	6 (60.0%)	3 (30.0%)	
Pulsating Sensation			0.060
Yes	0 (0.0%)	3 (30.0%)	
No	10 (0.0%)	7 (70.0%)	
Warm Sensation			1.000
Yes	0 (0.0%)	0 (0.0%)	
No	10 (100.0%)	10 (100.0%)	
Pressure			1.000
Yes	0 (0.0%)	0 (0.0%)	
No	10 (100.0%)	10 (100.0%)	
Pain			1.000
Yes	0 (0.0%)	0 (0.0%)	
No	10 (100.0%)	10 (100.0%)	
Dull Ache			1.000
Yes	0 (0.0%)	0 (0.0%)	
No	10 (100.0%)	10 (100.0%)	
Numbness			1.000
Yes	0 (0.0%)	0 (0.0%)	
No	10 (100.0%)	10 (100.0%)	
Overall Tolerability of Treatment			0.060
Very Comfortable	8 (80.0%)	6 (60.0%)	
Comfortable	0 (0.0%)	3 (30.0%)	
Neutral	2 (20.0%)	1 (10.0%)	
Uncomfortable	0 (0.0%)	0 (0.0%)	
Very Uncomfortable	0 (0.0%)	0 (0.0%)	

Note: *Independent samples t-tests were used for continuous variables, and Chi-Square Test was used for categorical variables. *A p-value of 0.05 was considered statistically significant.*

Effects of taVNS plus Exercise on Motor Function

Both groups demonstrated significant improvements in MDS-UPDRS Part III scores over time (active: $p = 0.011$, $\eta p^2 = 0.395$; sham: $p = 0.016$, $\eta_p^2 = 0.370$, **Figure 4)**. Post-hoc analyses revealed a significant reduction from baseline to post-test in both groups (active: $p = 0.034$; sham: $p = 0.014$), likely reflecting the short-term benefits of PT. However, only the active taVNS group maintained significant improvements at follow-up (baseline vs. follow-up: $p = 0.018$), whereas the sham group exhibited a regression toward baseline motor function ($p = 0.500$).



Figure 3. MDS-UPDRS Part III Scores by treatment group over three time points (baseline, post-test, and follow-up). Within-group repeated measures ANOVA revealed a statistically significant effect of time for both groups (active: $F(2,18)=5.886$, $p=0.011$; sham: $F(2,18)=5.281$, $p=0.016$). Post-hoc testing revealed significant changes between baseline and post-test in both groups (sham: $p=0.014$, active: $p=0.034$), however only the active group-maintained significance between baseline and follow-up ($p=0.018$).

In the sham group, there were no other significant changes in motor function over time. In contrast, the active taVNS group exhibited a significant increase in distance walked during the 6MWT (baseline: 1390.04 ± 126.22, post-test: 1556.00 ± 196.41, follow-up: 1505.22 ± 173.10; $p = 0.045$, $\eta_p^2 = 0.386$). Post-hoc comparisons show a significant improvement from baseline and post-test ($p = 0.020$). However, this improvement was not sustained at follow-up ($p = 0.173$), suggesting acute benefits to CV endurance that diminished without continued intervention. Significant improvements in dynamic balance were also observed, as measured by the FGA (baseline: 25.00 ± 3.43, post-test: 28.60 ± 2.17, follow-up: 27.69 ± 2.80; $p = 0.001$, $\eta_p^2 = 0.531$) and the Mini-BESTest (baseline: 22.30 ± 2.54, post-test: 25.70 ± 1.16, follow-up: 25.80 ± 2.04, $p < 0.001$, $\eta_p^2 = 0.640$). Post-hoc analyses revealed immediate improvements from baseline to post-test (FGA: $p = 0.001$; Mini-BESTest: $p < 0.001$), and importantly, these gains were sustained at follow-up (FGA: $p = 0.016$; Mini-BESTest: $p < 0.001$), suggesting lasting changes in balance performance. Within group results are fully presented in **Tables 3 and 4**. There were no significant

differences observed between groups for the MDS-UPDRS Part III, 6MWT, FGA, or mini-BEST test (**Table 6**).

Table 3. Within-Group Analysis of Motor Outcomes for Sham taVNS plus PT

Test	Timepoint	Mean (SD)	F (df)	p-value	η_p^2	Post-hoc (p-values)
MDS-UPDRS Part III	Baseline Post Follow-up	36.7 (8.60) 26.8 (12.51) 32.3 (8.52)	F(2,18)=5.281	**0.016***	0.370	Baseline vs. Post: **p=0.014*** Baseline vs. Follow-up: p=0.500 Post vs. Follow-up: p=0.265
6MWT	Baseline Post Follow-up	1368.9 (299.06) 1449.4 (346.20) 1430.13 (297.69)	F(2,14)=1.375	0.285	0.164	
mCTSIB	Baseline Post Follow-up	182.20 (71.39) 175.60 (59.47) 197.10 (76.29)	F(2,18)=2.203	0.139	0.197	
FGA	Baseline Post Follow-up	22.70 (4.08) 24.40 (3.44) 24.40 (3.77)	F(2,18)=1.565	0.236	0.148	
10MWT (ss)	Baseline Post Follow-up	5.10 (0.59) 5.31 (0.81) 5.24 (0.69)	F(2,18)=0.430	0.657	0.046	
10MWT (fs)	Baseline Post Follow-up	3.80 (0.51) 3.78 (0.59) 3.94 (0.52)	F(2,18)=0.939	0.409	0.094	
miniBEST	Baseline Post Follow-up	20.90 (3.78) 25.70 (1.16) 25.80 (2.04)	F(1.28, 11.52)=2.22†	0.161	0.198	

Note: *Repeated Measures ANOVA was used to assess within-group differences over time. † Greenhouse-Geisser correction was applied for violations of sphericity where indicated. Bonferroni post-hoc tests were conducted for significant time effects. * P-values of <0.05 were considered statistically significant. Partial eta squared (η^2_p) effect sizes: small (0.01–0.05), medium (0.06–0.13), large (>0.14).*

Table 4. Within-Group Analysis of Motor Outcomes for Active taVNS plus PT

Test	Timepoint	Mean (SD)	F (df)	p-value	η_p^2	Post-hoc (p-values)
MDS-UPDRS Part III	Baseline Post Follow-up	31.00 (12.69) 25.10 (11.51) 24.50 (9.97)	F(2,18)=5.886	**0.011***	0.395	Baseline vs. Post: **p=0.034*** Baseline vs. Follow-up: **p=0.018*** Post vs. Follow-up: p=1.000
6MWT	Baseline Post Follow-up	1390.04 (126.22) 1566.00 (196.41) 1505.22 (173.10)	F(1.20,9.63)=5.029†	**0.045***	0.386	Baseline vs. Post: **p=0.020*** Baseline vs. Follow-up: p=0.173 Post vs. Follow-up: p=0.890
mCTSIB	Baseline Post Follow-up	226.00 (87.33) 217.40 (84.07) 197.60 (68.45)	F(2,18)=1.838	0.188	0.170	

FGA	Baseline	25.00 (3.43)	F(2,18)=10.201	**0.001***	0.531	Baseline vs. Post: **p=0.001*** Baseline vs. Follow-up: **p=0.016***
	Post	28.60 (2.17)				Post vs. Follow-up: p=0.720
	Follow-up	27.69 (2.80)				
10MWT (ss)	Baseline	5.02 (0.59)	F(2,18)=0.272	0.765	0.029	
	Post	5.02 (0.67)				
	Follow-up	5.10 (0.58)				
10MWT (fs)	Baseline	3.63 (0.25)	F(2,18)=1.450	0.261	0.139	
	Post	3.53 (0.29)				
	Follow-up	3.47 (0.27)				
miniBEST	Baseline	22.30 (2.54)	F(2,18)=16.02	**<0.001***	0.640	Baseline vs. Post: **p<0.001*** Baseline vs. Follow-up: **p<0.001***
	Post	25.70 (1.16)				Post vs. Follow-up: p=1.000
	Follow-up	25.80 (2.04)				

Note: *Repeated Measures ANOVA was used to assess within-group differences over time. † Greenhouse-Geisser correction was applied for violations of sphericity where indicated. Bonferroni post-hoc tests were conducted for significant time effects. * P-values of <0.05 were considered statistically significant. Partial eta squared (η^2_p) effect sizes: small (0.01–0.05), medium (0.06–0.13), large (>0.14).*

Effects of taVNS and Exercise on Cardiovascular Activity

A summary of CV activity including HR, DBP, and SBP in response to taVNS and exercise for both groups is presented in **Table 5** and **Figure 5**. In the sham group, only SBP decreased significantly post-taVNS (pre: 128.53 ± 12.50, post: 120.84 ± 11.78; p=0.023, CI: 2.17, 13.21, d = 0.996). In contrast, active taVNS significantly reduced SBP, DBP, and HR, all with large effect sizes (SBP pre: 130.21 ± 9.86, post: 121.50 ± 6.93, p<0.001, CI: 5.11, 12.31, d: 1.729; DBP pre: 75.93 ± 6.07, post: 73.09 ± 5.04, p=0.003, CI: 1.26, 4.42, d: 1.284; HR pre: 71.54 ± 12.25, post: 69.85 ± 11.44, p=0.027, CI: 0.24, 3.15, d: -0.834).

As expected, both groups showed expected HR increases after exercise (sham: p<0.001, CI: -13.09, -4.86, d = -1.559; active: p<0.001, CI: -26.71, -16.04, d = -2.865). However, between-group comparisons indicate that this difference was statistically significant between groups (p<0.001, CI: -18.66, -6.14, d: -1.86, **Table 6**), with the active group demonstrating a more robust increase in HR (21.37 ± 7.46 point change) compared to sham (8.98 ± 5.76 point change). Together these trends indicate that active taVNS acutely modulates CV function at rest, which results in a more dynamic CV response when administered immediately prior to exercise.



Figure 4. Average Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Heart Rate (HR), of both sham and active groups, measured at three time points: pre-taVNS, post-taVNS, and immediately post-exercise. Paired samples t-tests were used to assess within group differences and independent samples t-tests were used to assess between group differences. Within the sham group, a significant difference was observed in SBP pre-post taVNS and in HR pre taVNS-post exercise. Within the active group, a significant difference was observed in SBP, DBP, and HR pre-post taVNS and in SBP and HR pre taVNS-post exercise. A significant between-group difference was observed in HR post-exercise. A significant difference (*) indicates a p-valve of <0.05.

Table 5. Within-Group Analysis of the Effects of taVNS and Exercise on CV Function

Condition	Mean (SD)	p	95% CI	Cohn's d
Sham Group				
SBP				
Pre taVNS	128.53 (12.50)	**0.012***	2.17, 13.21	0.996
Post taVNS	120.84 (11.78)			
Post exercise	134.01 (14.91)	0.058	-11.18, 0.23	-0.687
DBP				
Pre taVNS	76.76 (6.19)	0.255	-1.13, 3.76	0.385
Post taVNS	75.44 (6.54)			
Post exercise	78.05 (7.20)	0.099	-2.88, 0.30	-0.582
HR				
Pre taVNS	74.91 (9.61)	0.367	-0.66, 1.61	0.300
Post taVNS	74.44 (8.96)			
Post exercise	83.89 (11.29)	**<0.001***	-13.09, -4.86	-1.559
Active Group				
SBP				
Pre taVNS	130.21 (9.86)	**<0.001***	5.11, 12.31	1.729
Post taVNS	121.50 (6.93)			
Post exercise	137.60 (15.11)	0.056*	-15.02, 0.24	-0.693
DBP				
Pre taVNS	75.93 (6.07)	**0.003***	1.26, 4.42	1.284
Post taVNS	73.09 (5.04)			
Post exercise	77.26 (6.68)	0.235	-3.69, 1.03	-0.403
HR				
Pre taVNS	71.54 (12.25)	**0.027***	0.24, 3.15	0.834
Post taVNS	69.85 (11.44)			
Post exercise	92.91 (9.42)	**<0.001***	-26.71, -16.04	-2.865

Note: *Paired sample t-tests were used to assess changes in SBP, DBP, and HR over time within each treatment group. The first comparison assessed changes in SBP, DBP and HR from pre-taVNS to post-taVNS. The second comparison assessed changes in SBP, DBP, -Biserial and HR from pre-taVNS to post-exercise. Effect sizes were calculated using Cohn's d, where values of 0.1–0.3 indicate a small effect, 0.3–0.5 indicate a medium effect, and greater than or equal to 0.5 indicate a large effect. *A p-value of less than 0.05 was considered statistically significant.*

Table 6. Between-Group Analysis of Motor and Cardiovascular Outcomes

Test	Timepoint	Mean (SD)	p-value	95% CI	Cohn's d
MDS-UPDRS Part III	Δ Baseline to Post	Sham: -9.90 (8.63) Active: -5.90 (8.03)	0.298	-11.84, 3.84	-0.480
	Δ Baseline to F/U	Sham: -4.40 (8.67) Active: -6.50 (5.67)	0.529	-4.78, 8.98	0.287
6MWT	Δ Baseline to Post	Sham: 64.67 (162.94) Active: 175.96 (159.01)	0.162	-272.17, 49.59	-0.691
	Δ Baseline to F/U	Sham: 83.89 (150.22) Active: 132.06 (109.55)	0.432	-174.46, 78.12	-0.370
FGA	Δ Baseline to Post	Sham: 1.70 (3.43) Active: 3.60 (2.32)	0.164	-4.65, 0.85	-0.649
	Δ Baseline to F/U	Sham: 1.30 (3.27) Active: 2.60 (3.17)	0.378	-4.32, 1.72	-0.404
Mini-BEST	Δ Baseline to Post	Sham: 1.90 (3.57) Active: 3.40 (2.46)	0.289	-4.38, 1.38	-0.489
	Δ Baseline to F/U	Sham: 1.30 (3.23) Active: 2.60 (3.17)	0.106	-4.92, 0.52	-0.761

SBP	Δ pre-taVNS to post-taVNS	Sham: -7.69 (7.72) Active: -8.71 (5.04)	0.730	-5.10, 7.15	0.157
	Δ pre-taVNS to post-exercise	Sham: 5.48 (7.97) Active: 7.39 (10.67)	0.655	-10.76, 6.94	-0.203
DBP	Δ pre-taVNS to post-taVNS	Sham: -1.32 (3.42) Active: -2.84 (2.21)	0.252	-1.18, 4.23	0.529
	Δ pre-taVNS to post-exercise	Sham: 1.29 (2.22) Active: 1.33 (3.30)	0.987	-2.68, 2.61	-0.013
HR	Δ pre-taVNS to post-taVNS	Sham: -0.48 (1.58) Active: -1.70 (2.03)	0.151	-0.49, 2.93	0.671
	Δ pre-taVNS to post-exercise	Sham: 8.98 (5.76) Active: 21.37 (7.46)	**<0.001***	-18.66, -6.14	-1.860

*Note: Independent samples t-tests were used to assess between-group differences. For all motor outcomes (MDS-UPDRS Part III, 6MWT, FGA, and miniBEST), the first comparison evaluates differences in change scores from baseline to post-test assessments. The second comparison evaluates differences in change scores from baseline to follow-up. For all cardiovascular outcomes (SBP, DBP, and HR), the first comparison evaluates differences in changes scores from pre-taVNS to post-taVNS. The second comparison evaluates differences in change scores from pre-taVNS to post-exercise. Effect sizes were calculated using Cohn's, where values of 0.1–0.3 indicate a small effect, 0.3–0.5 indicate a medium effect, and greater than or equal to 0.5 indicate a large effect. *A p-value of less than 0.05 was considered statistically significant.*

DISCUSSION

Overview

PT is a widely prescribed, non-pharmacologic therapy for PD. Exercise promotes increased neurotrophic factor expression[39], dopamine transmission[40], corticomotor excitability[41], and grey matter volume[42] in PD patients. However, the exercise intensity and frequency that drives these physiologic changes can be difficult to achieve in real-world clinical settings because of interference from time constraints, burden of care, and dysautonomia or impaired cardiovascular dynamics. Therefore, interventions that address these barriers could the increased translation of exercise research into clinical practice.

Transcutaneous auricular Vagus Nerve Stimulation (taVNS) is a non-invasive neuromodulation method that could bridge this gap. taVNS enhances neuroplasticity and improves motor learning and consolidation in rehabilitation medicine by acting in part on the activity of the locus coeruleus (LC)-norepinephrine (NE) signaling[32-34,43,44]. Additionally, taVNS acutely modulates CV activity[45], potentially offsetting PD-related dysautonomia. Given the broad usage of TENS in PT clinical practice, taVNS could potentially be integrated into practice to both facilitate cortical plasticity, neuroadaptation[9,46,47], and CV response to exercise. This pilot study assesses the safety and feasibility of a combined taVNS plus PT intervention and identify trends in outcomes to inform future study design.

Feasibility, Safety & Tolerability of Combining taVNS with Exercise in PD

The safety and tolerability of taVNS has been widely established in healthy adults[26]. Additionally, taVNS has been explored as a standalone treatment for PD patients, with no significant adverse events reported to date[29,30,48]. This study extends those findings, demonstrating that combining taVNS with exercise is feasible, safe, and well-tolerated in PD. We were successfully able to recruit, enroll, and retain the target number of participants, with low dropout rates and zero adverse events during taVNS itself nor during exercise. The results of the tolerability survey suggest that the treatment is comfortable and acceptable from a patient experience standpoint, which is critical for clinical translation, as interventions that are not well-tolerated or perceived positively by patients are unlikely to be adopted. These findings justify a Phase II trial to formally assess efficacy of this intervention in a larger sample size.

Combining taVNS with PT to Promote Lasting Motor Benefits

While both groups showed short-term improvements in motor function as measured by the MDS-UPDRS Part III, sustained improvements in the active group suggest that taVNS promotes longer-lasting

effects than PT alone. This raises the possibility that taVNS can facilitate motor learning or enhance neuroplastic consolidation, which has been explored in other populations[17,47,49] and is particularly relevant for progressive neurodegenerative diseases such as PD, where maintaining function is a clinical priority. The lack of sustained improvement in the sham group may reflect the transient therapeutic benefits from PT without neuromodulatory support.

Additionally, while the MDS-UPDRS Part III is considered the gold standard for assessing motor symptom severity in PD, it may not fully capture changes in functional capacity that are directly targeted by rehabilitation interventions. The observed immediate and lasting improvements in measures of clinical balance (FGA, mini-BEST) in the active group suggest that taVNS enhances the functional impact of PT itself, aligning with the principle of training specificity[50]. The PWR! Moves program emphasizes large-amplitude, dynamic movement patterns, so improvements in tests of dynamic balance are not surprising. These findings further support the hypothesis that taVNS strengthens the consolidation and retention of task-specific motor gains in PD rehabilitation.

Autonomic Modulation and CV Benefits of taVNS-Augmented Exercise

Short-term improvements in CV endurance, as measured by the 6MWT, were observed in the active group only, potentially reflecting transient modulation of autonomic function during each session. This hypothesis is further supported by acute reductions in SBP, DBP, and HR with active taVNS at rest, as well as a more robust HR response to exercise in the active group, suggesting enhanced autonomic adaptability. This reduction in HR and BP support the hypothesis that noninvasive vagal modulation can produce effects like those produced by pharmacological agonists of alpha-2 adrenergic receptors (i.e. clonidine) while acting on LC-NE circuits[51]. Interestingly, taVNS has been shown to affect both autonomic arousal and cortical plasticity through modulation of the LC-NE system. Our results suggest these dual outcomes can produce unique benefits for patients with PD by acting to stabilize CV dynamics and enhance exercise-mediated plasticity. Given dysautonomia is highly prevalent in PD and can blunt CV response to exertion[52-54], our observations indicate taVNS can improve CV dynamics and thus augment the effectiveness of exercise-based interventions. Future studies using continuous or dynamic CV monitoring are warranted to better characterize these effects and explore their implications for exercise dosing and safety. Additionally, the inclusion of more precise fitness measures such as HRV, resting heart rate, or VO_2 max can help clarify the physiological pathways by which taVNS supports exercise tolerance in individuals with PD.

Limitations & Future Directions

This study has several potential limitations. First, the small sample size limits the statistical power and precludes definitive conclusions about efficacy. Second, the single-blinded design also introduces potential bias, particularly given the challenge of participant blinding at perceptible stimulation intensities. Future studies should include separate, blinded assessors as well as explore the influence of sub-perceptual stimulation intensity to ensure a truly double-blinded study design. Additionally, additional pulse profiles should be examined to identify optimal therapeutic dosage. Furthermore, only individuals with mild-moderate PD were enrolled, limiting generalizability to those with more advanced disease. The follow-up period was also relatively short, and longer-term follow-up outcomes (e.g., 6–12 months) are needed to assess the durability of treatment effects. CV function was assessed only at discrete time points (pre-taVNS, post-taVNS, and post-exercise). Continuous CV monitoring including HRV may provide a more comprehensive understanding of how taVNS affects autonomic modulation. Additionally, only one exercise modality was used. While functionally oriented, it remains unclear whether other exercise modalities, such as CV endurance training or task-specific rehabilitation, may yield greater benefits when combined with taVNS. Finally, no direct measures of neuroplasticity were collected. Future trials incorporating neuroimaging or neurophysiological outcomes are needed to elucidate underlying mechanisms.

Conclusion

Combining taVNS with PT is feasible, safe, and tolerable for individuals with mild-moderate idiopathic PD. Our observations indicate that taVNS acutely modulates CV activity at rest and during exercise. The data also indicate taVNS plus PT results in greater improvements in motor function compared to PT alone, and these benefits can be retained over time, indicating increased and lasting neuroplastic change. However, further clinical studies are required to draw definitive conclusions about efficacy. The results of this study indicate taVNS combined with PT is a promising, scalable, and viable therapeutic option for patients suffering from PD.

REFERENCES

1. Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. *Clinics in Geriatric Medicine*. Feb 2020;36(1):1-+. doi:10.1016/j.cger.2019.08.002
2. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease. *Movement Disorders*. Aug 2018;33(8):1248-1266. doi:10.1002/mds.27372
3. Dashtipour K, Johnson E, Kani C, et al. Effect of exercise on motor and nonmotor symptoms of Parkinson's disease. *Parkinsons Dis*. 2015;2015:586378. doi:10.1155/2015/586378
4. Ellis T, Boudreau JK, DeAngelis TR, et al. Barriers to exercise in people with Parkinson disease. *Phys Ther*. May 2013;93(5):628-36. doi:10.2522/ptj.20120279
5. Schootemeijer S, van der Kolk NM, Ellis T, et al. Barriers and Motivators to Engage in Exercise for Persons with Parkinson’s Disease. *Journal of Parkinson's Disease*. 2020;10:1293-1299. doi:10.3233/JPD-202247
6. Evancho A, Tyler WJ, McGregor K. A review of combined neuromodulation and physical therapy interventions for enhanced neurorehabilitation. *Front Hum Neurosci*. 2023;17:1151218. doi:10.3389/fnhum.2023.1151218
7. Capilupi MJ, Kerath SM, Becker LB. Vagus Nerve Stimulation and the Cardiovascular System. *Cold Spring Harb Perspect Med*. Feb 3 2020;10(2)doi:10.1101/cshperspect.a034173
8. Pavlov VA, Tracey KJ. The vagus nerve and the inflammatory reflex--linking immunity and metabolism. *Nat Rev Endocrinol*. Dec 2012;8(12):743-54. doi:10.1038/nrendo.2012.189
9. Collins L, Boddington L, Steffan PJ, McCormick D. Vagus nerve stimulation induces widespread cortical and behavioral activation. *Curr Biol*. May 24 2021;31(10):2088-2098.e3. doi:10.1016/j.cub.2021.02.049
10. Martin KA, Papadoyannis ES, Schiavo JK, et al. Vagus nerve stimulation recruits the central cholinergic system to enhance perceptual learning. *Nature Neuroscience*. 2024/09/16 2024;doi:10.1038/s41593-024-01767-4
11. Olsen LK, Solis E, Jr., McIntire LK, Hatcher-Solis CN. Vagus nerve stimulation: mechanisms and factors involved in memory enhancement. *Front Hum Neurosci*. 2023;17:1152064. doi:10.3389/fnhum.2023.1152064
12. Ekmekyapar Fırat Y, Turgay T, Soğan SS, Günel Karadeniz P. Effects of LSVT-BIG via telerehabilitation on non-motor and motor symptoms and quality of life in Parkinson's disease. *Acta Neurol Belg*. Feb 2023;123(1):207-214. doi:10.1007/s13760-022-02104-x
13. Fleming Walsh S, Balster C, Chandler A, Brown J, Boehler M, O'Rear S. LSVT BIG® and long-term retention of functional gains in individuals with Parkinson's disease. *Physiother Theory Pract*. May 2022;38(5):629-636. doi:10.1080/09593985.2020.1780655
14. McDonnell MN, Rischbieth B, Schammer TT, Seaforth C, Shaw AJ, Phillips AC. Lee Silverman Voice Treatment (LSVT)-BIG to improve motor function in people with Parkinson's disease: a

systematic review and meta-analysis. *Clin Rehabil*. May 2018;32(5):607-618. doi:10.1177/0269215517734385
15. Peterka M, Odorfer T, Schwab M, Volkmann J, Zeller D. LSVT-BIG therapy in Parkinson's disease: physiological evidence for proprioceptive recalibration. *BMC Neurol*. Jul 11 2020;20(1):276. doi:10.1186/s12883-020-01858-2
16. Schenkman M, Moore CG, Kohrt WM, et al. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. *JAMA Neurol*. Feb 1 2018;75(2):219-226. doi:10.1001/jamaneurol.2017.3517
17. Keute M, Gharabaghi A. Brain plasticity and vagus nerve stimulation. *Auton Neurosci*. Dec 2021;236:102876. doi:10.1016/j.autneu.2021.102876
18. Dawson J, Liu CY, Francisco GE, et al. Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. *Lancet*. Apr 24 2021;397(10284):1545-1553. doi:10.1016/s0140-6736(21)00475-x
19. Ottaviani MM, Vallone F, Micera S, Recchia FA. Closed-Loop Vagus Nerve Stimulation for the Treatment of Cardiovascular Diseases: State of the Art and Future Directions. Review. *Frontiers in Cardiovascular Medicine*. 2022-April-07 2022;9doi:10.3389/fcvm.2022.866957
20. Griffith G, Lamotte G, Mehta N, et al. Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson's Disease. *J Parkinsons Dis*. 2024;14(1):121-133. doi:10.3233/jpd-230006
21. Panassollo TRB, Lord S, Rashid U, Taylor D, Mawston G. The effect of chronotropic incompetence on physiologic responses during progressive exercise in people with Parkinson's disease. *European Journal of Applied Physiology*. 2024/04/29 2024;doi:10.1007/s00421-024-05492-5
22. Low DA, Vichayanrat E, Iodice V, Mathias CJ. Exercise hemodynamics in Parkinson's disease and autonomic dysfunction. *Parkinsonism Relat Disord*. May 2014;20(5):549-53. doi:10.1016/j.parkreldis.2014.02.006
23. Deguchi K. [Impaired exercise-induced blood pressure control in patients with Parkinson's disease and related disorders]. *Rinsho Shinkeigaku*. 2013;53(11):1379-81. doi:10.5692/clinicalneurol.53.1379
24. Ben-Menachem E, Revesz D, Simon BJ, Silberstein S. Surgically implanted and non-invasive vagus nerve stimulation: a review of efficacy, safety and tolerability. *Eur J Neurol*. Sep 2015;22(9):1260-8. doi:10.1111/ene.12629
25. Verma N, Mudge JD, Kasole M, et al. Auricular Vagus Neuromodulation—A Systematic Review on Quality of Evidence and Clinical Effects. Systematic Review. *Frontiers in Neuroscience*. 2021-April-30 2021;15doi:10.3389/fnins.2021.664740
26. Kim AY, Marduy A, de Melo PS, et al. Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis. *Sci Rep*. Dec 21 2022;12(1):22055. doi:10.1038/s41598-022-25864-1
27. Urbin MA, Lafe CW, Simpson TW, Wittenberg GF, Chandrasekaran B, Weber DJ. Electrical stimulation of the external ear acutely activates noradrenergic mechanisms in humans. *Brain Stimulation*. 2021/07/01/ 2021;14(4):990-1001. doi:https://doi.org/10.1016/j.brs.2021.06.002
28. Evancho A, Do M, Fortenberry D, Billings R, Sartayev A, Tyler WJ. Vagus nerve stimulation in Parkinson's disease: a scoping review of animal studies and human subjects research. *NPJ Parkinsons Dis*. Oct 24 2024;10(1):199. doi:10.1038/s41531-024-00803-1
29. Zhang H, Cao XY, Wang LN, et al. Transcutaneous auricular vagus nerve stimulation improves gait and cortical activity in Parkinson's disease: A pilot randomized study. *CNS Neuroscience and Therapeutics*. 2023;29(12):3889-3900. doi:10.1111/cns.14309
30. Lench DH, Turner TH, McLeod C, et al. Multi-session transcutaneous auricular vagus nerve stimulation for Parkinson's disease: evaluating feasibility, safety, and preliminary efficacy. *Frontiers in Neurology*. 2023;14((Lench D.H.; Turner T.H.; Lovera L.; Heidelberg L.; Hinson V.K., hinsonvk@musc.edu) Department of Neurology, Medical University of South Carolina, Charleston, SC,

United States(McLeod C.) Department of Neurology, Augusta University Medical Center, Augusta)doi:10.3389/fneur.2023.1210103
31. Marano M, Anzini G, Saltarocchi L, et al. Left Vagus Stimulation Modulates Contralateral Subthalamic β Power Improving the Gait in Parkinson's Disease. *Movement Disorders*. 2023;((Marano M., m.marano@policlinicocampus.it; Anzini G.; Saltarocchi L.; Capone F.; Di Lazzaro V.) Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy(Marano M)doi:10.1002/mds.29690
32. Wang MH, Wang YX, Xie M, et al. Transcutaneous auricular vagus nerve stimulation with task-oriented training improves upper extremity function in patients with subacute stroke: a randomized clinical trial. *Front Neurosci*. 2024;18:1346634. doi:10.3389/fnins.2024.1346634
33. Shi X, Zhao J, Xu S, et al. Clinical Research Progress of the Post-Stroke Upper Limb Motor Function Improvement via Transcutaneous Auricular Vagus Nerve Stimulation. *Neural Plast*. 2023;2023:9532713. doi:10.1155/2023/9532713
34. Badran BW, Peng X, Baker-Vogel B, et al. Motor Activated Auricular Vagus Nerve Stimulation as a Potential Neuromodulation Approach for Post-Stroke Motor Rehabilitation: A Pilot Study. *Neurorehabil Neural Repair*. Jun 2023;37(6):374-383. doi:10.1177/15459683231173357
35. Farrand AQ, Verner RS, McGuire RM, Helke KL, Hinson VK, Boger HA. Differential effects of vagus nerve stimulation paradigms guide clinical development for Parkinson's disease. *Brain Stimulation*. 2020;13(5):1323-1332. doi:10.1016/j.brs.2020.06.078
36. Farrand AQ, Helke KL, Gregory RA, Gooz M, Hinson VK, Boger HA. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease. *Brain Stimulation*. 2017;10(6):1045-1054. doi:10.1016/j.brs.2017.08.008
37. Farley B. What are th PWR! Moves? Accessed June 19, 2025, https://www.pwr4life.org/moves/
38. Tickle-Degnen L. Nuts and bolts of conducting feasibility studies. *Am J Occup Ther*. 2013 Mar-Apr 2013;67(2):171-176. doi:10.5014/ajot.2013.006270
39. Hirsch MA, van Wegen EEH, Newman MA, Heyn PC. Exercise-induced increase in brain-derived neurotrophic factor in human Parkinson's disease: a systematic review and meta-analysis. *Transl Neurodegener*. 2018;7:7. doi:10.1186/s40035-018-0112-1
40. de Laat B, Hoye J, Stanley G, et al. Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease. *npj Parkinson's Disease*. 2024/02/09 2024;10(1):34. doi:10.1038/s41531-024-00641-1
41. Ginanneschi F, Messa LV, Battisti C, Rossi A. Changes in corticomotor pathway excitability after exercise training in Parkinson’s disease. *Neurological Sciences*. 2021/08/01 2021;42(8):3375-3381. doi:10.1007/s10072-020-04960-y
42. Silva-Batista C, Ragothaman A, Mancini M, et al. Cortical thickness as predictor of response to exercise in people with Parkinson's disease. *Hum Brain Mapp*. Jan 2021;42(1):139-153. doi:10.1002/hbm.25211
43. Badran BW, Jenkins DD, Cook D, et al. Transcutaneous Auricular Vagus Nerve Stimulation-Paired Rehabilitation for Oromotor Feeding Problems in Newborns: An Open-Label Pilot Study. *Front Hum Neurosci*. 2020;14:77. doi:10.3389/fnhum.2020.00077
44. Redgrave JN, Moore L, Oyekunle T, et al. Transcutaneous Auricular Vagus Nerve Stimulation with Concurrent Upper Limb Repetitive Task Practice for Poststroke Motor Recovery: A Pilot Study. *J Stroke Cerebrovasc Dis*. Jul 2018;27(7):1998-2005. doi:10.1016/j.jstrokecerebrovasdis.2018.02.056
45. Carandina A, Rodrigues GD, Di Francesco P, et al. Effects of transcutaneous auricular vagus nerve stimulation on cardiovascular autonomic control in health and disease. *Auton Neurosci*. Dec 2021;236:102893. doi:10.1016/j.autneu.2021.102893
46. Biggio F, Gorini G, Utzeri C, et al. Chronic vagus nerve stimulation induces neuronal plasticity in the rat hippocampus. *International Journal of Neuropsychopharmacology*. 2009;12(9):1209-1221.
47. Hays SA, Rennaker RL, Kilgard MP. Targeting plasticity with vagus nerve stimulation to treat neurological disease. *Progress in brain research*. 2013;207:275-299.

48. van Midden V, Simončič U, Pirtošek Z, Kojović M. The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait-A Randomized Motion Sensor Study. *Mov Disord*. Aug 2024;39(8):1375-1385. doi:10.1002/mds.29826
49. Tyler WJ, Wyckoff S, Hearn T, Hool N. The Safety and Efficacy of Transdermal Auricular Vagal Nerve Stimulation Earbud Electrodes for Modulating Autonomic Arousal, Attention, Sensory Gating, and Cortical Brain Plasticity in Humans. *bioRxiv*. 2019:732529. doi:10.1101/732529
50. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. *J Speech Lang Hear Res*. Feb 2008;51(1):S225-39. doi:10.1044/1092-4388(2008/018)
51. Tyler WJ, Boasso AM, Mortimore HM, et al. Transdermal neuromodulation of noradrenergic activity suppresses psychophysiological and biochemical stress responses in humans. *Scientific Reports*. 2015/09/10 2015;5(1):13865. doi:10.1038/srep13865
52. Kanegusuku H, Cucato GG, Longano P, et al. Acute Cardiovascular Responses to Self-selected Intensity Exercise in Parkinson's Disease. *Int J Sports Med*. Feb 2022;43(2):177-182. doi:10.1055/a-1529-6480
53. Kanegusuku H, Silva-Batista C, Peçanha T, et al. Blunted Maximal and Submaximal Responses to Cardiopulmonary Exercise Tests in Patients With Parkinson Disease. *Arch Phys Med Rehabil*. May 2016;97(5):720-5. doi:10.1016/j.apmr.2015.12.020
54. Roberson KB, Signorile JF, Singer C, et al. Hemodynamic responses to an exercise stress test in Parkinson's disease patients without orthostatic hypotension. *Appl Physiol Nutr Metab*. Jul 2019;44(7):751-758. doi:10.1139/apnm-2018-0638

ACKNOWLEDGEMENTS
Funding was provided by the UAB School of Health Professions Junior Faculty Development Grant.

DISCOLSURES WJT is a co-founder of IST, LLC and an inventor and co-inventor on neuromodulation methods and devices for treating various disorders. All other authors declare no financial or non-financial competing interests.